New drug NM6603 enters first human tests for advanced cancers
NCT ID NCT07292038
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called NM6603 in about 30 adults with advanced solid tumors (mainly colorectal or triple-negative breast cancer) who have run out of standard options. The main goal is to find the safest dose and check how the drug moves through the body. Participants receive the drug and are monitored closely for side effects and tumor response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center (SYSUCC)
RECRUITINGGuangzhou, Guangdong, 510060, China
-
The First Affiliated Hospital of Xiamen University
RECRUITINGXiamen, Fujian, 361001, China
-
The First Affiliated Hospital of Zhengzhou University
RECRUITINGZhengzhou, Henan, 450052, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a High-Fiber diet shield the gut during breast cancer therapy?
- Can mapping tumor DNA unlock personalized breast cancer care?
- Can a Two-Pronged antibody boost Chemo's power against a tough breast cancer?
- Can a new drug rally the immune system against Hard-to-Treat cancers?
- Could an oral chemo pill improve breast cancer treatment?
- Can a new drug combo shrink Hard-to-Treat colorectal tumors?